Literature DB >> 7570939

Transfusion-transmitted human parvovirus B19 infection in a thalassemic patient.

A Zanella1, F Rossi, C Cesana, A Foresti, F Nador, A S Binda, G Lunghi, M D Cappellini, M Furione, G Sirchia.   

Abstract

BACKGROUND: Human parvovirus (HPV) B19 infection has been shown to be transmissible by clotting factor concentrates, most often resulting in asymptomatic seroconversion. So far, no case of B19 transmission due to single-donor transfusion has been documented. CASE REPORT: A case of transfusion-transmitted HPV B19 infection in a 22-year-old female thalassemia major patient is described. She presented with an aplastic crisis; this was followed 1 week later by transitory heart failure and acute tricuspid incompetence. The echocardiogram revealed a grade III tricuspid regurgitation and a floating vegetation on the atrial face of the tricuspid lateral leaflet. The tricuspid regurgitation and vegetation spontaneously disappeared within 15 days. Blood cultures for bacteria were repeatedly negative. IgM anti-HPV B19 seroconversion was documented in the acute phase. B19 DNA was detected by polymerase chain reaction and remained detectable up to 4 months after diagnosis. High-titer IgM anti-HPV and B19 DNA were also found in serum samples collected at the time of donation from one of the donors of the blood transfused before the onset of clinical symptoms.
CONCLUSION: This case documents the transmission of HPV B19 by the transfusion of 1 red cell unit and the occurrence of possible transient cardiac involvement in this infectious complication.

Entities:  

Mesh:

Year:  1995        PMID: 7570939     DOI: 10.1046/j.1537-2995.1995.35996029163.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  9 in total

1.  Parvovirus B19 - Revised.

Authors:  Johannes Blümel; Reinhard Burger; Christian Drosten; Albrecht Gröner; Lutz Gürtler; Margarethe Heiden; Martin Hildebrandt; Bernd Jansen; Thomas Montag-Lessing; Ruth Offergeld; Georg Pauli; Rainer Seitz; Uwe Schlenkrich; Volkmar Schottstedt; Johanna Strobel; Hannelore Willkommen; Carl-Heinz Wirsing von König
Journal:  Transfus Med Hemother       Date:  2010-11-17       Impact factor: 3.747

2.  11 Adverse Reactions.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

Review 3.  Parvovirus B19: an expanding spectrum of disease.

Authors:  B Cohen
Journal:  BMJ       Date:  1995-12-09

4.  Parvovirus B19 infection transmitted by transfusion of red blood cells confirmed by molecular analysis of linked donor and recipient samples.

Authors:  Mei-Ying W Yu; Harvey J Alter; Maria Luisa A Virata-Theimer; Yansheng Geng; Li Ma; Cathy A Schechterly; Camilla A Colvin; Naomi L C Luban
Journal:  Transfusion       Date:  2010-02-12       Impact factor: 3.157

Review 5.  Advances in human B19 erythrovirus biology.

Authors:  Annabelle Servant-Delmas; Jean-Jacques Lefrère; Frédéric Morinet; Sylvie Pillet
Journal:  J Virol       Date:  2010-07-14       Impact factor: 5.103

6.  Detection and differentiation of human parvovirus variants by commercial quantitative real-time PCR tests.

Authors:  Kati Hokynar; Päivi Norja; Harri Laitinen; Pekka Palomäki; Antoine Garbarg-Chenon; Annamari Ranki; Klaus Hedman; Maria Söderlund-Venermo
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

7.  A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion.

Authors:  Steven H Kleinman; Simone A Glynn; Tzong-Hae Lee; Leslie H Tobler; Karen S Schlumpf; Deborah S Todd; Hannah Qiao; Mei-Ying W Yu; Michael P Busch
Journal:  Blood       Date:  2009-08-17       Impact factor: 22.113

8.  Serological study on parvovirus B19 infection in multitransfused thalassemia major patients and its transmission through donor units.

Authors:  Janak Kishore; Manisha Srivastava; Nabajyoti Choudhury
Journal:  Asian J Transfus Sci       Date:  2011-07

Review 9.  Parvovirus B19: What Is the Relevance in Transfusion Medicine?

Authors:  David Juhl; Holger Hennig
Journal:  Front Med (Lausanne)       Date:  2018-02-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.